CompletedNCT01640080
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
This study evaluated the effectiveness of Esketamine for people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Esketamine for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Dave and 8 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: June 27, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Belgium, Germany, Poland
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT01640080
- Official title
Show the full official title
A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression
Get this study by email
Recruitment & locations
CompletedDave, Belgium · Ghent, Belgium · Kortenberg, Belgium
6 more locations
- Lede, Belgium
- Berlin, Germany
- Freiburg im Breisgau, Germany
- Mainz, Germany
- München, Germany
- Gdansk, Poland
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Esketamine for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide